Integrated Antenatal Screening for HIV, Syphilis, and Hepatitis B Virus (HBV) in Pregnant Women in Burkina Faso and The Gambia

Status: Recruiting
Location: See all (2) locations...
Intervention Type: Other
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY

The TRI-MOM program aims to implement and evaluate a simplified (based on inexpensive rapid diagnostic tests), integrated (in governmental health facilities) and coordinated (between health care workers) strategy for the triple elimination of HIV, syphilis and HBV mother-to-child transmission (MTCT) in nine maternal and child health services, 5 in Burkina Faso and 5 in The Gambia. The TRI-MOM program has two components: 1. an intervention component consisting of a pilot study to reinforce the antenatal screening and prevention of MTCT (PMTCT) capacities for the 3 targeted infections through the implementation of a simplified, integrated and coordinated strategy of triple elimination of MTCT. 2. an evaluation component which will assess the impact of the TRI-MOM strategy on PMTCT services, reduction of HBV MTCT and women empowerment.

Eligibility
Participation Requirements
Sex: Female
Healthy Volunteers: t
View:

• Women attending a postnatal visit in one of the selected maternities (no maternal age limit)

Locations
Other Locations
Burkina Faso
Centre Muraz/INSP
NOT_YET_RECRUITING
Bobo-dioulasso
Gambia
MRC The Gambia at LSHTM
RECRUITING
Fajara
Contact Information
Primary
Lauren Perieres, PhD
lauren.perieres@inserm.fr
+33 4.91.32.46.00
Time Frame
Start Date: 2024-03-18
Estimated Completion Date: 2025-05
Participants
Target number of participants: 2800
Treatments
Experimental: TRI-MOM
Women attending their first postnatal visit in one of the selected maternities (no maternal age limit) will be eligible to participate in the study
Sponsors
Collaborators: Centre Muraz, Young Gambian Mums Fund, Medical Research Council, REVS PLUS Burkina Faso, National AIDS Control Program Gambia, Institut Pasteur
Leads: Institut de Recherche pour le Developpement

This content was sourced from clinicaltrials.gov